Replimune stock.

Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Nov 24, 2023 · The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ... The shares of common stock and the pre-funded warrants described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping ...

To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ...Earnings announcements can affect a stock's price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Aug 8, 2023 at 1:30 PM EDT. Jefferies Global Healthcare Conference. Jun 8, 2023 at 1:00 PM EDT. Piper Sandler Spring Biopharma Symposium. May 17 - May 18, 2023. Jefferies Biotech on the Bay Summit. Mar 16, 2023. Barclays Global Healthcare Conference. Mar 15, 2023 at 2:05 PM EDT.

Mutual fund, Stake, Shares owned, Total value ($), Shares bought / sold, Total change. T Rowe Price New Horizons Fund, 4.14%, 2,444,774, 35,620,357, -840 ...View 13F filing holders of Replimune Group Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. ... *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page*** Elevate your investments Try it for free. We give you the access and tools ...Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.Replimune Group - REPL - Stock Price Today - Zacks Replimune Group (REPL) (Delayed Data from NSDQ) $10.40 USD +0.08 (0.78%) Updated Nov 17, 2023 …

Replimune has assembled a world-class leadership team who together pioneered the development of the first and only FDA-approved oncolytic immunotherapy. Supported by renowned scientists, clinicians, and advisors, we are working to advance the field by developing optimally designed tumor-directed oncolytic immunotherapies to treat a broad …

Get the latest Replimune Group Inc. (REPL) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.Indeed, Replimune Group (NASDAQ:REPL) stock is up 152% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all ...He joins Ankyra from Replimune, where he served as the chief accounting officer and was responsible for financial, accounting, tax and human resources functions, and played a key role in the company’s successful 2018 initial public offering. Before Replimune, he served as vice president, finance and administration at uniQure. ...14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown.Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Replimune overview. Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co …Replimune overview. Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co …The stock of Replimune Group Inc (REPL) has gone up by 13.26% for the week, with a -15.10% drop in the past month and a -44.22% drop in the past quarter. The volatility ratio for the week is 7.61%, and the volatility levels for the past 30 days are 9.26% for REPL. The simple moving […]Replimune Group, Inc. Common Stock (REPL) Earnings Report Date | Nasdaq. Created with Sketch. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock ...Replimune Group is now considered extended and out of buy range after clearing a 20.23 buy point in a first-stage cup with handle.See if the stock forms a new pattern or follow-on buying ...

Nov 24, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Replimune Group stock is Buy based on the current 6 buy ratings for REPL. The average twelve-month price prediction for Replimune Group is $51.33 with a high price target of $70.00 and a low price target of $34.00. Learn more on REPL's analyst rating history.

Real time Replimune Group (REPL) stock price quote, stock graph, news & analysis. Earnings for Replimune Group are expected to decrease in the coming year, from ($3.53) to ($3.93) per share. Replimune Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 8th, 2024 based off prior year's report dates.Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.29 Jun 2020 ... The offering consisted of shares of Replimune's common stock and pre‑funded warrants to acquire shares of its common stock. The shares were ...In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 4,200,000 shares of its common stock at a purchase price of $23.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share ...Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe stock had previously closed at $10.40. Specifically, insider Konstantinos Xynos sold 7,313 shares of Replimune Group stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $10.92, for a total transaction of $79,857.96.

37 Salaries (for 31 job titles) • Updated Oct 29, 2023. How much do Replimune employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. Our model gets smarter over time as more people …

Christopher Sarchi REPL stock SEC Form 4 insiders trading. Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023.. The largest trade Christopher's ever made was selling 5,255 …

Founded Date Mar 2015. Founders Philip Sparke, Robert Coffin. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Replimune Group Inc. Stock Symbol NASDAQ:REPL. Company Type For Profit. Contact Email [email protected]. Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the …Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The REPL shares have gain 12.70% over the last week, with a monthly amount drifted -18.05%, and not seem to be holding up well overFiscal Q2 2024 ended 9/30/23. Get the latest Replimune Group Inc (REPL) real-time quote, historical performance, charts, and other financial information to help you make more …Barclays has chosen Biomea Fusion (BMEA), Replimune (REPL), Syndax (SNDX) and Iovance (IOVA) as its top picks in the small and mid-cap oncology space for the latter half of 2023.Dec 1, 2023 · View Replimune Group, Inc REPL investment & stock information. Get the latest Replimune Group, Inc REPL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.Replimune Group, Inc. Common Stock (REPL) Earnings Report Date | Nasdaq. Created with Sketch. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock ...Nov 27, 2023 · November 29, 2023. $11.32. 786,621. 1:1. $11.67. $11.95. $11.26. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently …Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.Today's High Today's Low 52 Week High 52 Week Low FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | | 3M | | YTD | | | | Max |

A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Replimune Group Stock Performance Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of …Instagram:https://instagram. northface stock2023 corvette z06 70th anniversary priceim better insurancevanguard institutional index fund institutional shares vinix Philip Astley-Sparke is a businessperson who founded Replimune Group, Inc. and who has been at the head of 6 different companies. He occupies the position of Chief Executive Officer & Director at Replimune Group, Inc. and Venture Partner at Forbion Capital Partners Management Holding BV. He previously held the position of Chairman at uniQure NV ...Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The REPL shares have gain 12.70% over the last week, with a monthly amount drifted -18.05%, and not seem to be holding up well over vornado realty2024 amg gle 63 s coupe Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune Group adaptive biotechnologies stock Replimune has assembled a world-class leadership team who together pioneered the development of the first and only FDA-approved oncolytic immunotherapy. Supported by renowned scientists, clinicians, and advisors, we are working to advance the field by developing optimally designed tumor-directed oncolytic immunotherapies to treat a broad …Nov 18, 2023 · Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023. The largest trade Christopher's ever made was selling 5,255 units of Replimune Inc stock on 16 November 2023 worth over $57,385. PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …